Arcutis Biotherapeutics (ARQT)

Executive Summary

Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on topical treatments for immune-mediated dermatological diseases. Its lead product, Zoryve (roflumilast) cream 0.3%, is approved for plaque psoriasis and seborrheic dermatitis, generating growing revenue as the company expands its commercial footprint. The company’s pipeline includes roflumilast foam for scalp psoriasis (Phase 3 completed, under FDA review) and a Phase 3 program for atopic dermatitis, where positive data have been reported and a supplemental New Drug Application (sNDA) is under review. Additionally, Arcutis is exploring roflumilast foam in hidradenitis suppurativa (Phase 2 recruiting) and has an earlier-stage asset ARQ-252 for vitiligo, though development was terminated. With a proprietary formulation platform enabling once-daily dosing and favorable safety profiles, Arcutis aims to address significant unmet needs in dermatology. The company's near-term growth is driven by label expansions for Zoryve, increased market penetration, and potential approval for atopic dermatitis, which would expand the addressable patient population substantially. Despite competition from established therapies, Arcutis' differentiated efficacy and convenience position it well for continued commercial success.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on sNDA for roflumilast cream in atopic dermatitis70% success
• Q4 2026Phase 2 data readout for roflumilast foam in hidradenitis suppurativa50% success
• Q3 2026Potential FDA approval for roflumilast foam in scalp psoriasis80% success